arrow
C

C. Michel Zwaan

department of pediatric oncology
H指数:29
被引数:2,564

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation

基于I期剂量发现试验 (ITCC-054/COG AAML1921) 和儿科推荐的II期剂量评估,博舒替尼在费城染色体阳性慢性粒细胞白血病患儿中的群体药代动力学

2026-07-270
OA
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study

Isatuximab联合化疗用于复发/难治性急性淋巴细胞白血病或急性髓系白血病的儿科患者:ISAKIDS研究

2025-10-300
OAAI
A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia
LEUKEMIA
IF13.4
2024-08-261
OAAI
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials
2024-08-010
OAAI
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial
2023-10-196
PRE
Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
2023-09-112
PRE
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia
2023-02-2330
OAAI
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

复发或难治性急性淋巴细胞白血病患儿接受inotuzumab ozogamicin治疗后嵌合抗原受体T细胞治疗的结果

LEUKEMIA
IF13.4
2022-10-309
PRE
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Inotuzumab ozogamicin作为复发和难治性急性淋巴细胞白血病患儿的单一药物: II期试验的结果

LEUKEMIA
IF13.4
2022-04-2536
OAAI